18:17 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
20:30 , Oct 9, 2018 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
00:38 , Oct 9, 2012 |  BC Extra  |  Financial News

Affimed raises EUR 15.5M in series D

Affimed Therapeutics AG (Heidelberg, Germany) raised EUR 15.5 million ($20.1 million) in a series D round led by existing investors Aeris Capital; BioMedInvest; LSP-Life Sciences Partners; Novo Nordisk A/S (CSE:NVO; NYSE:NVO); and OrbiMed. Affimed's AFM13...
08:00 , Dec 10, 2007 |  BioCentury  |  Product Development

Targeting CD19

Targeting CD19...
07:00 , Apr 9, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biotech venture investing hit record levels in the first quarter, totaling nearly $2 billion. That exceeds the previous high of more than $1.7 billion in the fourth quarter of 2000. VCs cited two reasons for...
00:40 , Apr 5, 2007 |  BC Extra  |  Financial News

Affimed raises EUR 25 million

Affimed (Heidelberg, Germany) raised EUR 25 million ($33.4 million) in a series B round co-led by BioMedInvest; OrbiMed Advisors; Life Sciences Partners; and firstVentury. Affimed has three tetravalent antibodies in preclinical testing: AFM11 and AFM12...